作者: Armand Bensussan , Jean Kadouche , Laurence Boumsell
DOI:
关键词:
摘要: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 as well pharmaceutical compositions containing them, are useful inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.